Immuneed

Immuneed originated from research at Uppsala University and is focused on developing innovative prostate cancer vaccines that harness the body's immune system to target tumor cells. The company operates as a contract research organization, specializing in the research and development of therapeutic cancer vaccine drugs. Its expertise includes immunotoxicology and immunophenotyping using human whole-blood assays, with a particular emphasis on monoclonal antibodies. Immuneed aims to provide medical institutions and health organizations with cutting-edge solutions that enhance peptide uptake and stimulate cellular immune activation, ultimately contributing to advancements in cancer treatment.